These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

430 related articles for article (PubMed ID: 30854331)

  • 1. Harnessing Radiation Biology to Augment Immunotherapy for Glioblastoma.
    Rajani KR; Carlstrom LP; Parney IF; Johnson AJ; Warrington AE; Burns TC
    Front Oncol; 2018; 8():656. PubMed ID: 30854331
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination immunotherapy strategies for glioblastoma.
    Chan HY; Choi J; Jackson C; Lim M
    J Neurooncol; 2021 Feb; 151(3):375-391. PubMed ID: 33611705
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Checkpoint: Inspecting the barriers in glioblastoma immunotherapies.
    Preddy I; Nandoliya K; Miska J; Ahmed AU
    Semin Cancer Biol; 2022 Nov; 86(Pt 3):473-481. PubMed ID: 35150865
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PD-1/PD-L1 immune checkpoint inhibitors in glioblastoma: clinical studies, challenges and potential.
    Yang T; Kong Z; Ma W
    Hum Vaccin Immunother; 2021 Feb; 17(2):546-553. PubMed ID: 32643507
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rationale for combination of therapeutic antibodies targeting tumor cells and immune checkpoint receptors: Harnessing innate and adaptive immunity through IgG1 isotype immune effector stimulation.
    Ferris RL; Lenz HJ; Trotta AM; García-Foncillas J; Schulten J; Audhuy F; Merlano M; Milano G
    Cancer Treat Rev; 2018 Feb; 63():48-60. PubMed ID: 29223828
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Trials Investigating Immune Checkpoint Blockade in Glioblastoma.
    Maxwell R; Jackson CM; Lim M
    Curr Treat Options Oncol; 2017 Aug; 18(8):51. PubMed ID: 28785997
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the CTLA-4/B7 axes in glioblastoma: preclinical evidence and clinical interventions.
    Fathi M; Razavi SM; Sojoodi M; Ahmadi A; Ebrahimi F; Namdar A; Hojjat-Farsangi M; Gholamin S; Jadidi-Niaragh F
    Expert Opin Ther Targets; 2022 Nov; 26(11):949-961. PubMed ID: 36527817
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model.
    Reardon DA; Gokhale PC; Klein SR; Ligon KL; Rodig SJ; Ramkissoon SH; Jones KL; Conway AS; Liao X; Zhou J; Wen PY; Van Den Abbeele AD; Hodi FS; Qin L; Kohl NE; Sharpe AH; Dranoff G; Freeman GJ
    Cancer Immunol Res; 2016 Feb; 4(2):124-35. PubMed ID: 26546453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The future of glioblastoma therapy: synergism of standard of care and immunotherapy.
    Patel MA; Kim JE; Ruzevick J; Li G; Lim M
    Cancers (Basel); 2014 Sep; 6(4):1953-85. PubMed ID: 25268164
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combinatorial approaches to effective therapy in glioblastoma (GBM): Current status and what the future holds.
    Asija S; Chatterjee A; Yadav S; Chekuri G; Karulkar A; Jaiswal AK; Goda JS; Purwar R
    Int Rev Immunol; 2022; 41(6):582-605. PubMed ID: 35938932
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Barriers to overcoming immunotherapy resistance in glioblastoma.
    Gillette JS; Wang EJ; Dowd RS; Toms SA
    Front Med (Lausanne); 2023; 10():1175507. PubMed ID: 37275361
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy as a New Therapeutic Approach for Brain and Spinal Cord Tumors.
    Medikonda R; Pant A; Lim M
    Adv Exp Med Biol; 2023; 1394():73-84. PubMed ID: 36587382
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overcoming the immune suppressive nature of glioblastoma by leveraging the surgical intervention - current status and future perspectives.
    Duerinck J; Tuyaerts S; Movahedi K; Neyns B
    Front Immunol; 2023; 14():1183641. PubMed ID: 37275902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Driver Mutations Dictate the Immunologic Landscape and Response to Checkpoint Immunotherapy of Glioblastoma.
    Yeo AT; Shah R; Aliazis K; Pal R; Xu T; Zhang P; Rawal S; Rose CM; Varn FS; Appleman VA; Yoon J; Varma H; Gygi SP; Verhaak RGW; Boussiotis VA; Charest A
    Cancer Immunol Res; 2023 May; 11(5):629-645. PubMed ID: 36881002
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune Checkpoint in Glioblastoma: Promising and Challenging.
    Huang J; Liu F; Liu Z; Tang H; Wu H; Gong Q; Chen J
    Front Pharmacol; 2017; 8():242. PubMed ID: 28536525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current trends in glioblastoma multiforme treatment: radiation therapy and immune checkpoint inhibitors.
    Nicholas S; Mathios D; Ruzevick J; Jackson C; Yang I; Lim M
    Brain Tumor Res Treat; 2013 Apr; 1(1):2-8. PubMed ID: 24904882
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The CNS and the Brain Tumor Microenvironment: Implications for Glioblastoma Immunotherapy.
    Desland FA; Hormigo A
    Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33027976
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G.
    Carosella ED; Ploussard G; LeMaoult J; Desgrandchamps F
    Eur Urol; 2015 Aug; 68(2):267-79. PubMed ID: 25824720
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current Immunotherapies for Glioblastoma Multiforme.
    Huang B; Li X; Li Y; Zhang J; Zong Z; Zhang H
    Front Immunol; 2020; 11():603911. PubMed ID: 33767690
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapy for the treatment of breast cancer: checkpoint blockade, cancer vaccines, and future directions in combination immunotherapy.
    McArthur HL; Page DB
    Clin Adv Hematol Oncol; 2016 Nov; 14(11):922-933. PubMed ID: 27930644
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.